AccScience Publishing / MI / Online First / DOI: 10.36922/MI025520142
Submit to MI
Cite this article
1
Download
25
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW ARTICLE

The role of engineered microbes in immune modulation across cancer, autoimmunity, and infection

Ola A. Al-Ewaidat1 ,  Moawiah M. Naffaa2*
Show Less
1 Department of Internal Medicine, School of Medicine, Stanford University, Palo Alto, California, United States of America
2 Independent Researcher, Mountain View, California, United States of America
MI, 025520142 https://doi.org/10.36922/MI025520142
Received: 28 December 2025 | Revised: 8 March 2026 | Accepted: 13 April 2026 | Published online: 8 May 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
XML
Cite
Abstract

Engineered microbes are emerging as a new class of living immunotherapeutics. Unlike conventional biologics or cell therapies with fixed mechanisms, these systems can sense and respond to dynamic tissue environments. They integrate environmental, metabolic, and immunological cues and process these signals through programmable biological circuits, executing context-dependent immune modulation with spatial and temporal precision. This review proposes an immune-centered paradigm shift for understanding engineered microbes. We conceptualize them as distributed immune-computational systems composed of sensing, signal processing, memory, and effector modules embedded within host immune networks. Rather than organizing the field by microbial taxonomy or disease category, we focus on immune logic. We describe how engineered microbes detect immune state signals, interpret these inputs through synthetic circuits, and generate outputs that activate, suppress, educate, or reprogram immunity. Applications across cancer, autoimmunity, and infection are discussed with attention to disease-specific immune requirements. We further define immune safety architecture as a core design principle, which includes inflammatory control, tolerance preservation, adaptive regulation, and mechanisms for therapeutic termination. Finally, we outline translational and regulatory considerations, emphasizing immune state-resolved evaluation rather than static pharmacologic endpoints. Together, this paradigm shift positions engineered microbes as programmable immune-modulating systems and provides a conceptual foundation for the rational development of next-generation living immunotherapies.

Keywords
Engineered microbial therapeutics
Living immunotherapies
Immune computation
Systems immunology
Cancer immunomodulation
Immune tolerance engineering
Immune safety architecture
Immune state endpoints
Funding
None.
Conflict of interest
The authors declare no conflict of interest.
References
  1. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-1365. doi: 10.1126/science.aar6711
  2. Yang F, Shi K, Jia YP, Hao Y, Peng JR, Qian ZY. Advanced biomaterials for cancer immunotherapy. Acta Pharmacol Sin. 2020;41(7):911-927. doi: 10.1038/s41401-020-0372-z
  3. Gurbatri CR, Arpaia N, Danino T. Engineering bacteria as interactive cancer therapies. Science. 2022;378(6622):858- 864. doi: 10.1126/science.add9667
  4. Kim TH, Cho BK, Lee DH. Synthetic Biology-Driven Microbial Therapeutics for Disease Treatment. J Microbiol Biotechnol. 2024;34(10):1947-1958. doi: 10.4014/jmb.2407.07004
  5. Muhammad S, Li M, Jia Q, et al. Advances in the engineering of living probiotics for cancer immunotherapy. Theranostics. 2026;16(3):1164-1226. doi: 10.7150/thno.125301
  6. Wang Y, Xiao S, Yu W, Han B, Guo G. Engineering bacteria for enhanced tumor therapy: from surface modification to synthetic genetic circuits. J Hematol Oncol. 2025;19(1). doi: 10.1186/s13045-025-01766-3
  7. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016;16(6):341-352. doi: 10.1038/nri.2016.42
  8. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-141. doi: 10.1016/j.cell.2014.03.011
  9. Chien T, Doshi A, Danino T. Advances in bacterial cancer therapies using synthetic biology. Curr Opin Syst Biol. 2017;5:1-8. doi: 10.1016/j.coisb.2017.05.009
  10. Lavrador P, Gaspar VM, Mano JF. Engineering mammalian living materials towards clinically relevant therapeutics. EBioMedicine. 2021;74:103717. doi: 10.1016/j.ebiom.2021.103717
  11. Armstrong A, Isalan M. Engineering bacterial theranostics: from logic gates to in vivo applications. Front Bioeng Biotechnol. 2024;12:1437301. doi: 10.3389/fbioe.2024.1437301
  12. Zhao L, Xin J, Hu M, Xue C, Dong N. Programmable microbial therapeutics: advances in engineered bacteria for targeted in vivo delivery and precision medicine. J Adv Res. 2025. doi: 10.1016/j.jare.2025.10.028
  13. Isabella VM, Ha BN, Castillo MJ, et al. Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol. 2018;36(9):857-864. doi: 10.1038/nbt.4222
  14. Zheng JH, Nguyen VH, Jiang SN, et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci Transl Med. 2017;9(376):eaak9537. doi: 10.1126/scitranslmed.aak9537
  15. Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, Danino T. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat Med. 2019;25(7):1057-1063. doi: 10.1038/s41591-019-0498-z
  16. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(8):600. doi: 10.1038/nri2614
  17. Belkaid Y, Harrison OJ. Homeostatic Immunity and the Microbiota. Immunity. 2017;46(4):562-576. doi: 10.1016/j.immuni.2017.04.008
  18. Omer R, Mohsin MZ, Mohsin A, et al. Engineered Bacteria-Based Living Materials for Biotherapeutic Applications. Front Bioeng Biotechnol. 2022;10:870675. doi: 10.3389/fbioe.2022.870675
  19. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2015;126(8):1048. doi: 10.1182/blood-2015-07-656918
  20. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278-287. doi: 10.1038/nrc3236
  21. Rafii S, Mukherji D, Komaranchath AS, et al. Advancing CAR T-Cell Therapy in Solid Tumors: Current Landscape and Future Directions. Cancers. 2025;17(17):2898. doi: 10.3390/cancers17172898
  22. Li YR, Zhu Y, Fang Y, Lyu Z, Yang L. Emerging trends in clinical allogeneic CAR cell therapy. Med. 2025;6(8):100677. doi: 10.1016/j.medj.2025.100677
  23. Vincent F, Gianni D. The limitations of small molecule and genetic screening in phenotypic drug discovery. Cell Chem Biol. 2025;32(11):1310-1320. doi: 10.1016/j.chembiol.2025.10.008
  24. Xiang X, Zhou Z, Rao X, Jiang XR. Recent advances of engineered bacteria for therapeutic applications. Mol Ther. 2026;34(2):714-733. doi: 10.1016/j.ymthe.2025.11.013
  25. Zhou T, Wu J, Tang H, et al. Enhancing tumor-specific recognition of programmable synthetic bacterial consortium for precision therapy of colorectal cancer. NPJ Biofilms Microbiomes. 2024;10(1). doi: 10.1038/s41522-024-00479-8
  26. Riglar DT, Silver PA. Engineering bacteria for diagnostic and therapeutic applications. Nat Rev Microbiol. 2018;16(4):214- 225. doi: 10.1038/nrmicro.2017.172
  27. Arboleda-García A, Alarcon-Ruiz I, Boada-Acosta L, Boada Y, Vignoni A, Jantus-Lewintre E. Advancements in synthetic biology-based bacterial cancer therapy: A modular design approach. Crit Rev Oncol Hematol. 2023;190:104088. doi: 10.1016/j.critrevonc.2023.104088
  28. Chen H, Zhu Y, Zhang C, Hu L, Yang K. Engineered bacteria in tumor immunotherapy. Cancer Lett. 2014;589:216817. doi: 10.1016/j.canlet.2024.216817
  29. Kim K, Kang M, Cho BK. Systems and synthetic biology-driven engineering of live bacterial therapeutics. Front Bioeng Biotechnol. 2023;11:1267378. doi: 10.3389/fbioe.2023.1267378
  30. Lee J, McClure S, Weichselbaum RR, Mimee M. Designing live bacterial therapeutics for cancer. Adv Drug Deliv Rev. 2025;221:115579. doi: 10.1016/j.addr.2025.115579
  31. Kitada T, DiAndreth B, Teague B, Weiss R. Programming gene and engineered-cell therapies with synthetic biology. Science. 2018;359(6376):eaad1067. doi: 10.1126/science.aad1067
  32. Shi XR, Zhang YF, Zhou Y, Zou ZP, Ye BC. Engineered microbial sensors: providing a new paradigm for disease detection. J Mater Chem B. 2025;13(45):14535-14555. doi: 10.1039/D5TB01468A
  33. Zhou Y, Han Y. Engineered bacteria as drug delivery vehicles: Principles and prospects. Eng Microbiol. 2022;2(3):100034. doi: 10.1016/j.engmic.2022.100034
  34. Qin Y, You SH, Zhang Y, Venu A, Hong Y, Min JJ. Genetic Programming by Nitric Oxide-Sensing Gene Switch System in Tumor-Targeting Bacteria. Biosensors. 2023;13(2):266. doi: 10.3390/bios13020266
  35. Tanniche I, Behkam B. Engineered live bacteria as disease detection and diagnosis tools. J Biol Eng. 2023;17(1). doi: 10.1186/s13036-023-00379-z
  36. Niu L, Deng Z, Jin Y, Guan N, Ye H. Engineering oncolytic bacteria as precision cancer therapeutics: design principles, therapeutic strategies, and translational perspectives. Protein Cell. 2025. doi: 10.1093/procel/pwaf085
  37. Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116. doi: 10.1126/scitranslmed.3006504
  38. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. doi: 10.1016/s0140-6736(16)30173-8
  39. Zou ZP, Du Y, Fang TT, Zhou Y, Ye BC. Biomarker-responsive engineered probiotic diagnoses, records, and ameliorates inflammatory bowel disease in mice. Cell Host Microbe. 2023;31(2):199-212.e5. doi: 10.1016/j.chom.2022.12.004
  40. Brand A, Singer K, Koehl GE, et al. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 2016;24(5):657-671. doi: 10.1016/j.cmet.2016.08.011
  41. Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451-455. doi: 10.1038/nature12726
  42. Hwang IY, Tan MH, Koh E, Ho CL, Poh CL, Chang MW. Reprogramming microbes to be pathogen-seeking killers. ACS Synth Biol. 2013;3(4):228-237. doi: 10.1021/sb400077j
  43. Cubillos-Ruiz A, Guo T, Sokolovska A, et al. Engineering living therapeutics with synthetic biology. Nat Rev Drug Discov. 2021;20(12):941-960. doi: 10.1038/s41573-021-00285-3
  44. Fischbach MA, Segre JA. Signaling in Host-Associated Microbial Communities. Cell. 2016;164(6):1288-1300. doi: 10.1016/j.cell.2016.02.037
  45. Round JL, Palm NW. Causal effects of the microbiota on immune-mediated diseases. Sci Immunol. 2018;3(20):eaao1603. doi: 10.1126/sciimmunol.aao1603
  46. Roybal KT, Rupp LJ, Morsut L, et al. Precision Tumor Recognition by T Cells With Combinatorial Antigen- Sensing Circuits. Cell. 2016;164(4):770-779. doi: 10.1016/j.cell.2016.01.011
  47. Nissim L, Wu MR, Pery E, et al. Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy. Cell. 2017;171(5):1138-1150.e15. doi: 10.1016/j.cell.2017.09.049
  48. Del Vecchio D, Dy AJ, Qian Y. Control theory meets synthetic biology. J R Soc Interface. 2016;13(120):20160380. doi: 10.1098/rsif.2016.0380
  49. Sohka T, Heins RA, Phelan RM, Greisler JM, Townsend CA, Ostermeier M. An externally tunable bacterial band-pass filter. Proc Natl Acad Sci USA. 2009;106(25):10135-10140. doi: 10.1073/pnas.0901246106
  50. Shui S, Scheller L, Correia BE. Protein-based bandpass filters for controlling cellular signaling with chemical inputs. Nat Chem Biol. 2024;20(5):586-593. doi: 10.1038/s41589-023-01463-7
  51. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541-550. doi: 10.1038/s41591-018-0014-x
  52. Netea MG, Joosten LAB. Trained innate immunity: Concept, nomenclature, and future perspectives. J Allergy Clin Immunol. 2024;154(5):1079-1084. doi: 10.1016/j.jaci.2024.09.005
  53. Kalvapalle PB, Sridhar S, Silberg JJ, Stadler LB. Long-duration environmental biosensing by recording analyte detection in DNA using recombinase memory. Appl Environ Microbiol. 2024;90(4):e0236323. doi: 10.1128/aem.02363-23
  54. Huang BD, Kim D, Yu Y, Wilson CJ. Engineering intelligent chassis cells via recombinase-based MEMORY circuits. Nat Commun. 2025;15(1). doi: 10.1038/s41467-024-46755-1
  55. Sechkar K, Steel H, Perrino G, Stan GB. A coarse-grained bacterial cell model for resource-aware analysis and design of synthetic gene circuits. Nat Commun. 2024;15(1). doi: 10.1038/s41467-024-46410-9
  56. Stone A, Youssef A, Rijal S, Zhang R, Tian XJ. Context-dependent redesign of robust synthetic gene circuits. Trends Biotechnol. 2024;42(7):895-909. doi: 10.1016/j.tibtech.2024.01.003
  57. Byrom DP, Darlington APS. Genetic controllers for enhancing the evolutionary longevity of synthetic gene circuits in bacteria. Nat Commun. 2025;16(1). doi: 10.1038/s41467-025-63627-4
  58. Menuhin-Gruman I, Arbel-Groissman M, Naki D, Bergman S, Tuller T. AI-directed gene fusing prolongs the evolutionary half-life of synthetic gene circuits. Sci Adv. 2025;11(40):eadx0796. doi: 10.1126/sciadv.adx0796
  59. Scott SR, Hasty J. Quorum Sensing Communication Modules for Microbial Consortia. ACS Synth Biol. 2016;5(9):969-977. doi: 10.1021/acssynbio.5b00286
  60. Guo Y, Gao M, Jiang L, Huang H, Kang G, Yu H. Synthetic microbial consortia based on quorum-sensing for disease therapy. Bioresour Bioprocess. 2025;12(1). doi: 10.1186/s40643-025-00962-w
  61. Falà AK, Álvarez-Ordóñez A, Filloux A, Gahan CGM, Cotter PD. Quorum sensing in human gut and food microbiomes: Significance and potential for therapeutic targeting. Front Microbiol. 2022;13:1002185. doi: 10.3389/fmicb.2022.1002185
  62. Tan Q, Cao X, Zou F, Wang H, Xiong L, Deng S. Spatial Heterogeneity of Intratumoral Microbiota: A New Frontier in Cancer Immunotherapy Resistance. Biomedicines. 2025;13(5):1261. doi: 10.3390/biomedicines13051261
  63. Pignon E, Schaerli Y. Deciphering microbial spatial organization: insights from synthetic and engineered communities. ISME Commun. 2025;5(1):ycaf107. doi: 10.1093/ismeco/ycaf107
  64. Wang H, Zheng L, Yang C, et al. Probiotic-mediated tumor microenvironment reprogramming with protease-sensitive interleukin-15 and photothermal therapy. Cell Rep Med. 2025;6(6):102191. doi: 10.1016/j.xcrm.2025.102191
  65. Chen J, Chen J, Chen Y, et al. Engineering Bacteria as Living Therapeutics in Cancer Therapy. Adv Sci. 2025;12(4):2507820. doi: 10.1002/advs.202507820
  66. Campos GM, Americo MF, Dos Santos Freitas A, et al. Lactococcus lactis as an Interleukin Delivery System for Prophylaxis and Treatment of Inflammatory and Autoimmune Diseases. Probiotics Antimicrob Proteins. 2024;16(2):352-366. doi: 10.1007/s12602-023-10041-1
  67. Zou ZP, Zhang XP, Zhang Q, Yin BC, Zhou Y, Ye BC. Genetically engineered bacteria as inflammatory bowel disease therapeutics. Eng Microbiol. 2024;4(4):100167. doi: 10.1016/j.engmic.2024.100167
  68. Hayashi N, Lai Y, Fuerte-Stone J, Mimee M, Lu TK. Cas9- assisted biological containment of a genetically engineered human commensal bacterium and genetic elements. Nat Commun. 2024;15(1). doi: 10.1038/s41467-024-45893-w
  69. Rottinghaus AG, Ferreiro A, Fishbein SRS, Dantas G, Moon TS. Genetically stable CRISPR-based kill switches for engineered microbes. Nat Commun. 2022;13(1). doi: 10.1038/s41467-022-28163-5
  70. Cheng F, Soleimani Samarkhazan H, Khazaei Y. CRISPR-engineered microbiome: living therapeutics revolutionize blood cancer immunotherapy. NPJ Biofilms Microbiomes. 2025;12(1). doi: 10.1038/s41522-025-00882-9
  71. Pan S, Hsu JC, Hung KT, Ho CJ. Regulatory framework and challenges for live biotherapeutic products in Taiwan. J Food Drug Anal. 2025;33(2):97-105. doi: 10.38212/2224-6614.3540
  72. Neil K, Allard N, Grenier F, Burrus V, Rodrigue S. Highly efficient gene transfer in the mouse gut microbiota is enabled by the Incl(2) conjugative plasmid TP114. Commun Biol. 2020;3(1). doi: 10.1038/s42003-020-01253-0
  73. Zorea A, Pellow D, Levin L, et al. Plasmids in the human gut reveal neutral dispersal and recombination that is overpowered by inflammatory diseases. Nat Commun. 2024;15(1). doi: 10.1038/s41467-024-47272-x
  74. Mecacci S, Torregrosa-Barragán L, Asin-Garcia E, Smith RW. Multilayered safety framework for living diagnostics in the colon. Front Syst Biol. 2023;3:1240040. doi: 10.3389/fsysb.2023.1240040
  75. Redenti A, Im J, Redenti B, et al. Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature. 2024;635(8038):453-461. doi: 10.1038/s41586-024-08033-4
  76. Yue Y, Xin Q, Zhu Y, et al. Probiotic-based oral vaccine mucosal delivery system enabling genetically encoded dual-antigen arrays. Nat Commun. 2025;16(1). doi: 10.1038/s41467-025-66622-x
  77. Johnston CD, Wargo JA. Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol. 2024;45(12):931-933. doi: 10.1016/j.it.2024.11.007
  78. Chen YE, Bousbaine D, Veinbachs A, et al. Engineered skin bacteria induce antitumor T cell responses against melanoma. Science. 2023;380(6641):203-210. doi: 10.1126/science.abp9563
  79. Omolekan TO, Folahan JT, Tesfay MZ. Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer’s defenses. Front Immunol. 2025;16:1618751. doi: 10.3389/fimmu.2025.1618751
  80. Kouno T, Zeng S, Wang Y, et al. Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice. Alcohol Clin Exp Res. 2023;47(5):856-867. doi: 10.1111/acer.15048
  81. Chen W, Guo Q, Li H, et al. Engineered Probiotics Mitigate Gut Barrier Dysfunction Induced by Nanoplastics. Adv Sci. 2025;12(22):2417283. doi: 10.1002/advs.202417283
  82. Wu YQ, Zou ZP, Zhou Y, Ye BC. Dual engineered bacteria improve inflammatory bowel disease in mice. Appl Microbiol Biotechnol. 2024;108(1). doi: 10.1007/s00253-024-13163-w
  83. Wang C, Feng Q, Shi S, et al. The Rational Engineered Bacteria Based Biohybrid Living System for Tumor Therapy. Adv Healthc Mater. 2024;13(28):2401538. doi: 10.1002/adhm.202401538
  84. Wang H, Xu F, Yao C, et al. Engineering bacteria for cancer immunotherapy by inhibiting IDO activity and reprogramming CD8+ T cell response. Proc Natl Acad Sci USA. 2025;121(51):e2533734122. doi: 10.1073/pnas.2533734122
  85. Wang J, Wang J, Yu Z, et al. Targeting the Adenosine- Mediated Metabolic Immune Checkpoint with Engineered Probiotic for Enhanced Chemo-Immunotherapy. Adv Sci. 2025;12(15):2411813. doi: 10.1002/advs.202411813
  86. Ma Y, Hu Y, Liu H, et al. High-Lactate-Metabolizing Photosynthetic Bacteria Reprogram Tumor Immune Microenvironment. Adv Mater. 2024;36(36):2405930. doi: 10.1002/adma.202405930
  87. Frutos-Grilo E, Ana Y, Gonzalez-de Miguel J, Cardona-i-Collado M, Rodriguez-Arce I, Serrano L. Bacterial live therapeutics for human diseases. Mol Syst Biol. 2024;20(12):1261-1281. doi: 10.1038/s44320-024-00067-0
  88. Tseng CH, Wong S, Yu J, et al. Development of live biotherapeutic products: a position statement of Asia-Pacific Microbiota Consortium. Gut. 2025;74(5):706-713. doi: 10.1136/gutjnl-2024-334501
  89. Almansour N, Al-Rashed F, Choudhry K, et al. Gut microbiota: a promising new target in immune tolerance. Front Immunol. 2025;16:1607388. doi: 10.3389/fimmu.2025.1607388
  90. Wang Q, Meng Q, Chen Y, et al. Interaction between gut microbiota and immunity in health and intestinal disease. Front Immunol. 2025;16:1673852. doi: 10.3389/fimmu.2025.1673852
  91. Mkilima T. Engineering artificial microbial consortia for personalized gut microbiome modulation and disease treatment. Ann N Y Acad Sci. 2025;1548(1):29-55. doi: 10.1111/nyas.15352
  92. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20(1):142-152. doi: 10.1200/JCO.20.1.142
  93. Brahmer JR, Johnson ML, Cobo M, et al. JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes-Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies. JTO Clin Res Rep. 2021;2(2):100103. doi: 10.1016/j.jtocrr.2020.100103
  94. Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012;18(3):858-868. doi: 10.1158/1078-0432.CCR-11-2121
  95. Kim S, Ndwandwe C, Devotta H, Kareem L, Yao L, O’Mahony L. Role of the microbiome in regulation of the immune system. Allergol Int. 2025;74(2):187-196. doi: 10.1016/j.alit.2024.12.006
  96. Zhang X, Pan Q, Yao G, et al. Bacteroides fragilis and propionate synergize with low-dose methimazole to treat Graves’ disease. Microbiol Spectr. 2025;13(6):e0318624. doi: 10.1128/spectrum.03186-24
  97. Bui TNY, Paul A, Guleria S, O’Sullivan JM, Toldi G. Short-chain fatty acids-a key link between the gut microbiome and T-lymphocytes in neonates? Pediatr Res. 2025. doi: 10.1038/s41390-025-04075-0
  98. Sharma A, Sharma G, Im SH. Gut microbiota in regulatory T cell generation and function: mechanisms and health implications. Gut Microbes. 2025;17(1):2516702. doi: 10.1080/19490976.2025.2516702
  99. Tian K, Jing D, Lan J, Lv M, Wang T. Commensal microbiome and gastrointestinal mucosal immunity: Harmony and conflict with our closest neighbor. Immun Inflamm Dis. 2024;12(7):e1316. doi: 10.1002/iid3.1316
  100. Kopczyńska J, Kowalczyk M. The potential of short-chain fatty acid epigenetic regulation in chronic low-grade inflammation and obesity. Front Immunol. 2024;15:1380476. doi: 10.3389/fimmu.2024.1380476
  101. Tang W, Wei Y, Ni Z, Hou K, Luo XM, Wang H. IgA-mediated control of host-microbial interaction during weaning reaction influences gut inflammation. Gut Microbes. 2024;16(1):2323220. doi: 10.1080/19490976.2024.2323220
  102. Mooser C, Ronchi F, Limenitakis JP, et al. Diet-derived LPS determines intestinal IgA induction and repertoire characteristics independently of the microbiota. Immunity. 2025;58(7):1778-1793.e7. doi: 10.1016/j.immuni.2025.05.024
  103. Pietrzak B, Tomela K, Olejnik-Schmidt A, Mackiewicz A, Schmidt M. Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells. Int J Mol Sci. 2020;21(23):9524. doi: 10.3390/ijms21239524
  104. Chowdhury MR, Islam A, Yurina V, Shimosato T. Genetically Modified Lactic Acid Bacteria: a Promising Mucosal Delivery Vector for Vaccines. Probiotics Antimicrob Proteins. 2025;18(2):3094-3112. doi: 10.1007/s12602-025-10667-3
  105. Zhou M, Tang Y, Xu W, et al. Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies. Front Immunol. 2023;14:1140463. doi: 10.3389/fimmu.2023.1140463
  106. Liu S, Zhong Z, Tu Q, Jin M. Synthetic biology approaches to enhance cancer immune responses. Front Immunol. 2025;16:1698158. doi: 10.3389/fimmu.2025.1698158
  107. Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D. Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduct Target Ther. 2025;10(1). doi: 10.1038/s41392-025-02264-1
  108. Chen YH, Wu KH, Wu HP. Unraveling the Complexities of Toll-like Receptors: From Molecular Mechanisms to Clinical Applications. Int J Mol Sci. 2024;25(9):5037. doi: 10.3390/ijms25095037
  109. Huang Y, Piao L, Liu X. Enhancing Tumor-Specific immunity with SL(dacA): Attenuated Salmonella-mediated c-di-AMP delivery system targeting the STING pathway. Int J Pharm. 2024;666:124759. doi: 10.1016/j.ijpharm.2024.124759
  110. Al-Saafeen BH, Al-Sbiei A, Bashir G, et al. Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer. Front Immunol. 2022;13:1017780. doi: 10.3389/fimmu.2022.1017780
  111. Mowday AM, van de Laak JM, Fu Z, et al. Tumor-targeting bacteria as immune stimulants - the future of cancer immunotherapy? Crit Rev Microbiol. 2024;50(6):955-970. doi: 10.1080/1040841X.2024.2311653
  112. Li W, Li YA, Zhang Y, Shi H. Engineered Salmonella Enteritidis vector targeting innate immune molecules provides protection against Salmonella Enteritidis and Salmonella Typhimurium. Poult Sci. 2025;104(11):105724. doi: 10.1016/j.psj.2025.105724
  113. Damani-Yokota P, Khanna KM. Innate immune memory: The evolving role of macrophages in therapy. Elife. 2025;14:e108276. doi: 10.7554/eLife.108276
  114. Zhang S, Li R, Xu Y, et al. Engineered bacteria: Strategies and applications in cancer immunotherapy. Fundam Res. 2025;5(3):1327-1345. doi: 10.1016/j.fmre.2024.11.001
  115. Kato Y, Mori H. Genetically stable kill-switch using “demon and angel” expression construct of essential genes. Front Bioeng Biotechnol. 2024;12:1365870. doi: 10.3389/fbioe.2024.1365870
  116. Guo Y, Gao M, Wang L, et al. An Engineered Probiotic Consortium Based on Quorum-Sensing for Colorectal Cancer Immunotherapy. Adv Sci. 2025;12(46):2512744. doi: 10.1002/advs.202512744
  117. Matuszynska A, Ebenhoh O, Zurbriggen MD, Ducat DC, Axmann IM. A new era of synthetic biology-microbial community design. Synth Biol. 2024;9(1):ysae011. doi: 10.1093/synbio/ysae011
  118. Wu S, Zhou Y, Dai L, Yang A, Qiao J. Assembly of functional microbial ecosystems: from molecular circuits to communities. FEMS Microbiol Rev. 2024;48(6):fuae026. doi: 10.1093/femsre/fuae026
  119. Chen X, He C, Zhang Q, Bayakmetov S, Wang X. Modularized Design and Construction of Tunable Microbial Consortia with Flexible Topologies. ACS Synth Biol. 2024;13(1):183- 194. doi: 10.1021/acssynbio.3c00420
  120. Savage TM, Vincent RL, Rae SS, et al. Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity. Sci Adv. 2023;9(10):eadc9436. doi: 10.1126/sciadv.adc9436
  121. Guo P, Wang W, Xiang Q, et al. Engineered probiotic ameliorates ulcerative colitis by restoring gut microbiota and redox homeostasis. Cell Host Microbe. 2024;32(9):1502- 1518.e9. doi: 10.1016/j.chom.2024.07.028
  122. Furuichi M, Kawaguchi T, Pust MM, et al. Commensal consortia decolonize Enterobacteriaceae via ecological control. Nature. 2024;633(8031):878-886. doi: 10.1038/s41586-024-07960-6
  123. Li M, Liu N, Zhu J, et al. Engineered probiotics with sustained release of interleukin-2 for the treatment of inflammatory bowel disease after oral delivery. Biomaterials. 2024;309:122584. doi: 10.1016/j.biomaterials.2024.122584
  124. Li X, Zhou Z, Li W, et al. Design of stable and self-regulated microbial consortia for chemical synthesis. Nat Commun. 2022;13(1). doi: 10.1038/s41467-022-29215-6
  125. Nguyen N, Wang M, Li L, Chan CTY. A genetic safeguard for eliminating target genes in synthetic probiotics in a gut environment. iScience. 2025;28(8):113027. doi: 10.1016/j.isci.2025.113027
  126. Wang S, Zhan Y, Jiang X, Lai Y. Engineering Microbial Consortia as Living Materials: Advances and Prospectives. ACS Synth Biol. 2024;13(9):2653-2666. doi: 10.1021/acssynbio.4c00313
  127. Quiroga-Centeno AC, Atanasova K, Ebert MP, Thomann AK, Reindl W. Emerging microbiome-directed therapies in inflammatory bowel disease: beyond diet modification and FMT. Semin Immunopathol. 2025;47(1). doi: 10.1007/s00281-025-01066-5
  128. Zalatan JG, Petrini L, Geiger R. Engineering bacteria for cancer immunotherapy. Curr Opin Biotechnol. 2024;85:103061. doi: 10.1016/j.copbio.2023.103061
  129. Akbariqomi M, Kheirandish Zarandi P, Abedi A, Moosazadeh Moghaddam M, Imani Fooladi AA. Bacteria-based immunosuppressive tumor microenvironment reprogramming: a promising dawn in cancer therapy. Microb Cell Fact. 2025;24(1). doi: 10.1186/s12934-025-02838-2
  130. Zi G, Zhou W, Zhou L, Wang L, Zheng P, Wei S. Engineered Bacteria-Nano Hybrid System: The Intelligent Drug Factory for Next-Generation Cancer Immunotherapy. Pharmaceutics. 2025;17(10):1349. doi: 10.3390/pharmaceutics17101349
  131. Fan S, Zhu S, Wang W, et al. Current status and future perspectives of multi-modal bacteria-based cancer therapies. Clin Transl Med. 2025;15(10):e70485. doi: 10.1002/ctm2.70485
  132. Lu Y, Li Z, Xu H, et al. In situ enrichment and delivery of STING agonists by protamine-modified Salmonella for cancer immunotherapy. J Control Release. 2025;388:114284. doi: 10.1016/j.jconrel.2025.114284
  133. Wang B, Yu W, Jiang H, Meng X, Tang D, Liu D. Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects. Front Immunol. 2024;15:1485546. doi: 10.3389/fimmu.2024.1485546
  134. Nerdinger YG, Binder AK, Bremm F, Feuchter N, Schaft N, Dörrie J. STINGing Cancer: Development, Clinical Application, and Targeted Delivery of STING Agonists. Int J Mol Sci. 2025;26(18):9008. doi: 10.3390/ijms26189008
  135. Leventhal DS, Sokolovska A, Li N, et al. Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020;11(1). doi: 10.1038/s41467-020-16602-0
  136. Liao J, Pan H, Huang G. T cell cascade regulation initiates systemic antitumor immunity through living drug factory of anti-PD-1/IL-12 engineered probiotics. Cell Rep. 2024;43(4):114086. doi: 10.1016/j.celrep.2024.114086
  137. Tumas S, Meldgaard TS, Vaaben TH, et al. Engineered E. coli Nissle 1917 for delivery of bioactive IL-2 for cancer immunotherapy. Sci Rep. 2023;13(1). doi: 10.1038/s41598-023-39365-2
  138. Lin Z, Meng F, Ma Y, et al. In situ immunomodulation of tumors with biosynthetic bacteria promote anti-tumor immunity. Bioact Mater. 2024;32:12-27. doi: 10.1016/j.bioactmat.2023.09.007
  139. Naffaa MM, Al-Ewaidat OA, Gogia S, Begiashvili V. Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation. Explor Target Antitumor Ther. 2025;6:1002313. doi: 10.37349/etat.2025.1002313
  140. Nguyen DH, You SH, Ngo HT, et al. Reprogramming the tumor immune microenvironment using engineered dual-drug loaded Salmonella. Nat Commun. 2024;15(1). doi: 10.1038/s41467-024-50950-5
  141. Wang S, Cheng M, Chen CC, et al. Salmonella immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I interferon combination therapy. Oncoimmunology. 2024;13(1):2298444. doi: 10.1080/2162402X.2023.2298444
  142. Chen X, Zhao J, Yue S, et al. An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy. Nat Cancer. 2024;5(7):1063-1081. doi: 10.1038/s43018-024-00760-x
  143. Zhu J, Sun Y, Qian X, et al. Intranodal injection of neoantigen-bearing engineered Lactococcus lactis triggers epitope spreading and systemic tumor regressions. Acta Pharm Sin B. 2025;15(4):2217-2236. doi: 10.1016/j.apsb.2025.02.041
  144. Mao L, Xarpidin B, Shi R, et al. Natural Enzyme-Loaded Polymeric Stealth Coating-Armed Engineered Probiotics by Disrupting Tumor Lactate Homeostasis to Synergistic Metabolism-Immuno-Enzyme Dynamic Therapy. Adv Sci. 2025;12(16):2417172. doi: 10.1002/advs.202417172
  145. Luke JJ, Piha-Paul SA, Medina T, et al. Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies. Clin Cancer Res. 2023;29(13):2435- 2444. doi: 10.1158/1078-0432.CCR-23-0118
  146. Xie XT, Guan M, Cheng K, et al. Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy. Sci Adv. 2025;11(13):eadt7298. doi: 10.1126/sciadv.adt7298
  147. Li F, Yang Z, Savage TM, et al. Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms. Sci Immunol. 2024;9(100):eadn9879. doi: 10.1126/sciimmunol.adn9879
  148. Zhu C, Liu C, Wu Q, et al. Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors. Signal Transduct Target Ther. 2024;9(1). doi: 10.1038/s41392-024-02028-3
  149. Liu Z, Lim SH, Min JJ, Jung S. Synergistic Antitumor Effect of Combined Radiotherapy and Engineered Salmonella typhimurium in an Intracranial Sarcoma Mouse Model. Vaccines. 2023;11(7):1275. doi: 10.3390/vaccines11071275
  150. Singer ZS, Pabon J, Huang H, Rice C, Danino T. Engineered bacteria launch and control an oncolytic virus. Nat Biomed Eng. 2026;10(3):490-500. doi: 10.1038/s41551-025-01476-8
  151. Yurtseven B, Aydemir E, Ayaz F. The Role of Intestinal Microbiota and Immune System Interactions in Autoimmune Diseases. Immunotargets Ther. 2025;14:1347- 1372. doi: 10.2147/ITT.S569016
  152. Al-Ewaidat OA, Naffaa MM. Emerging AI- and Biomarker- Driven Precision Medicine in Autoimmune Rheumatic Diseases: From Diagnostics to Therapeutic Decision- Making. Rheumato. 2025;5(4):17. doi: 10.3390/rheumato5040017
  153. Liu Y, Cao X, Liu H, Zhang W. The crosstalk between probiotics and T cell immunity. Front Immunol. 2025;16:1695840. doi: 10.3389/fimmu.2025.1695840
  154. Song Y, Li J, Wu Y. Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. Signal Transduct Target Ther. 2025;10(1). doi: 10.1038/s41392-025-02525-z
  155. Omar TM, Alfarttoosi KH, Sanghvi G, et al. Engineering the Microbiome: a Novel Approach to Managing Autoimmune Diseases. Neuromolecular Med. 2025;27(1). doi: 10.1007/s12017-025-08879-5
  156. Duan S, Wang Y, Zhan S, et al. Engineered probiotics: a new era in treating inflammatory bowel disease. J Transl Med. 2025;23(1). doi: 10.1186/s12967-025-07271-y
  157. Han K, Xu J, Xie F, Crowther J, Moon JJ. Engineering Strategies to Modulate the Gut Microbiome and Immune System. J Immunol. 2024;212(2):208-215. doi: 10.4049/jimmunol.2300480
  158. Sadhu S, Paul T, Yadav N. Therapeutic engineering of the gut microbiome using synthetic biology and metabolic tools: a comprehensive review with E. coli Nissle 1917 as a model case study. Arch Microbiol. 2025;207(9). doi: 10.1007/s00203-025-04417-w
  159. Marquez-Paradas E, Torrecillas-Lopez M, Barrera- Chamorro L, et al. Microbiota-derived extracellular vesicles: current knowledge, gaps, and challenges in precision nutrition. Front Immunol. 2025;16:1599029. doi: 10.3389/fimmu.2025.1599029
  160. Melo-Marques I, Cardoso SM, Empadinhas N. Bacterial extracellular vesicles at the interface of gut microbiota and immunity. Gut Microbes. 2024;16(1):2396494. doi: 10.1080/19490976.2024.2396494
  161. Nie X, Li Q, Ji H, et al. Bifidobacterium longum NSP001- derived extracellular vesicles ameliorate ulcerative colitis by modulating T cell responses in gut microbiota-(in) dependent manners. NPJ Biofilms Microbiomes. 2025;11(1). doi: 10.1038/s41522-025-00663-4
  162. Kozakiewicz D, Razim A, Schabussova I, Gorska S. Immunomodulatory properties of probiotic extracellular vesicles- do they have the potential to fill the gap in therapeutic strategies for allergies? Cell Commun Signal. 2025;23(1). doi: 10.1186/s12964-025-02532-1
  163. Liu BD, Akbar R, Oliverio A, Thapa K, Wang X, Fan GC. Bacterial Extracellular Vesicles in the Regulation of Inflammatory Response and Host-Microbe Interactions. Shock. 2024;61(2):175-188. doi: 10.1097/SHK.0000000000002252
  164. Mathieu C, Wiedeman A, Cerosaletti K, et al. A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab. Diabetologia. 2024;67(1):27-41. doi: 10.1007/s00125-023-06014-2
  165. Xie M, Ma C, Wang X, et al. Transcriptomic Analysis of Immune Tolerance Induction in NOD Mice Following Oral Vaccination with GAD65-Lactococcus lactis. Vaccines. 2025;13(9):927. doi: 10.3390/vaccines13090927
  166. Dwyer AJ, Shaheen ZR, Fife BT. Antigen-specific T cell responses in autoimmune diabetes. Front Immunol. 2024;15:1440045. doi: 10.3389/fimmu.2024.1440045
  167. Takiishi T, Korf H, Van Belle TL, et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest. 2012;122(5):1717-1725. doi: 10.1172/JCI60530
  168. Kedmi R, Littman DR. Antigen-presenting cells as specialized drivers of intestinal T cell functions. Immunity. 2024;57(10):2269-2279. doi: 10.1016/j.immuni.2024.09.011
  169. Antonini Cencicchio M, Montini F, Palmieri V, et al. Microbiota-produced immune regulatory bile acid metabolites control central nervous system autoimmunity. Cell Rep Med. 2025;6(4):102028. doi: 10.1016/j.xcrm.2025.102028
  170. He L, Zhong Z, Wen S, Li P, Jiang Q, Liu F. Gut microbiota-derived butyrate restores impaired regulatory T cells in patients with AChR myasthenia gravis via mTOR-mediated autophagy. Cell Commun Signal. 2024;22(1). doi: 10.1186/s12964-024-01588-9
  171. Xia Y, Liu C, Li R, et al. Lactobacillus-derived indole-3- lactic acid ameliorates colitis in cesarean-born offspring via activation of aryl hydrocarbon receptor. iScience. 2023;26(11):108279. doi: 10.1016/j.isci.2023.108279
  172. Chen Y, Bi S, Zhang X, et al. Engineered probiotics remodel the intestinal epithelial barrier and enhance bacteriotherapy for inflammatory bowel diseases. Acta Biomater. 2025;198:467-481. doi: 10.1016/j.actbio.2025.04.016
  173. Laguna JG, Freitas ADS, Barroso FAL, et al. Recombinant probiotic Lactococcus lactis delivering P62 mitigates moderate colitis in mice. Front Microbiol. 2024;15:1309160. doi: 10.3389/fmicb.2024.1309160
  174. Yu M, Kim J, Ahn JH, Moon Y. Nononcogenic restoration of the intestinal barrier by E. coli-delivered human EGF. JCI Insight. 2019;4(16):e125166. doi: 10.1172/jci.insight.125166
  175. Rankin LC, Kaiser KA, de Los Santos-Alexis K, et al. Dietary tryptophan deficiency promotes gut RORgammat(+) Treg cells at the expense of Gata3(+) Treg cells and alters commensal microbiota metabolism. Cell Rep. 2023;42(3):112135. doi: 10.1016/j.celrep.2023.112135
  176. Xu Y, Xiong Z, Zhang P, et al. Microbiota metabolite taurodeoxycholic acid maintains intestinal tissue residency of innate lymphoid cells via engagement with P2Y10 receptor. Sci Adv. 2025;11(34):eadt9645. doi: 10.1126/sciadv.adt9645
  177. Zhu D, Galley J, Pizzini J. Microbial Biosensor for Sensing and Treatment of Intestinal Inflammation. Adv Sci. 2025;12(27):2504364. doi: 10.1002/advs.202504364
  178. Liu J, Wang L, Pang B, et al. Engineered probiotics platform for oral delivery of antibody as a high-compliance alternative for immune-mediated inflammatory diseases. Cell Rep Med. 2025:102523. doi: 10.1016/j.xcrm.2025.102523
  179. Weibel N, Curcio M, Schreiber A, et al. Engineering a Novel Probiotic Toolkit in Escherichia coli Nissle 1917 for Sensing and Mitigating Gut Inflammatory Diseases. ACS Synth Biol. 2024;13(8):2376-2390. doi: 10.1021/acssynbio.4c00036
  180. Gonzales-Luna AJ, Carlson TJ, Garey KW. Review Article: Safety of Live Biotherapeutic Products Used for the Prevention of Clostridioides difficile Infection Recurrence. Clin Infect Dis. 2023;77(Supplement_6):S487-S496. doi: 10.1093/cid/ciad642
  181. Jiang S, Zhang C, Han Z, et al. Native microbiome dominates over host factors in shaping the probiotic genetic evolution in the gut. NPJ Biofilms Microbiomes. 2023;9(1). doi: 10.1038/s41522-023-00447-8
  182. Kumar S, Hasty J. Stability, robustness, and containment: preparing synthetic biology for real-world deployment. Curr Opin Biotechnol. 2023;79:102880. doi: 10.1016/j.copbio.2022.102880
  183. Bjork JR, Bolte LA, Maltez Thomas A, et al. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nat Med. 2024;30(3):785-796. doi: 10.1038/s41591-024-02803-3
  184. Zhong F, Liu X, Wang X, Hou M, Guo L, Luo X. An AI-Designed Antibody-Engineered Probiotic Therapy Targeting Urease to Combat Helicobacter pylori Infection in Mice. Microorganisms. 2025;13(9):2043. doi: 10.3390/microorganisms13092043
  185. Carolak E, Czajkowska J, Stypułkowska A, Waszczuk W, Dutkiewicz A, Grzymajlo K. Being a better version of yourself: genetically engineered probiotic bacteria as host defense enhancers in the control of intestinal pathogens. Gut Microbes. 2025;17(1):2519696. doi: 10.1080/19490976.2025.2519696
  186. Kamble NS, Thomas S, Madaan T, et al. Engineered bacteria as an orally administered anti-viral treatment and immunization system. Gut Microbes. 2025;17(1):2500056. doi: 10.1080/19490976.2025.2500056
  187. Jin K, Huang Y, Che H, Wu Y. Engineered Bacteria for Disease Diagnosis and Treatment Using Synthetic Biology. Microb Biotechnol. 2025;18(1):e70080. doi: 10.1111/1751-7915.70080
  188. Huang L, Tang W, He L, et al. Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice. Nat Commun. 2024;15(1). doi: 10.1038/s41467-024-51182-3
  189. Deckers J, Anbergen T, Hokke AM, et al. Engineering cytokine therapeutics. Nat Rev Bioeng. 2023;1(4):304. doi: 10.1038/s44222-023-00030-y
  190. Carreto-Binaghi LE, Sztein MB, Booth JS. Role of cellular effectors in the induction and maintenance of IgA responses leading to protective immunity against enteric bacterial pathogens. Front Immunol. 2024;15:1446072. doi: 10.3389/fimmu.2024.1446072
  191. De Ponte Conti B, Marino R, Rezzonico-Jost T, et al. Secretory IgA amplification during immune checkpoint blockade enhances the control of tumor growth by enterotropic T cells. Sci Adv. 2025;11(40):eab5308. doi: 10.1126/sciadv.aeb5308
  192. Schluter T, van Elsas Y, Priem B, Ziogas A, Netea MG. Trained immunity: induction of an inflammatory memory in disease. Cell Res. 2025;35(11):792-802. doi: 10.1038/s41422-025-01171-y
  193. Li P, Liu M, Liu Y, et al. Recent Advances of Trained immunity in Macrophages. Int J Biol Sci. 2025;21(12):5258- 5283. doi: 10.7150/ijbs.115515
  194. Hao D, McBride MA, Bohannon JK, et al. Metabolic adaptations driving innate immune memory: mechanisms and therapeutic implications. J Leukoc Biol. 2025;117(5). doi: 10.1093/jleuko/qiaf037
  195. Kawai T, Ikegawa M, Ori D, Akira S. Decoding Toll-like receptors: Recent insights and perspectives in innate immunity. Immunity. 2024;57(4):649-673. doi: 10.1016/j.immuni.2024.03.004
  196. Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. Front Immunol. 2018;9:2936. doi: 10.3389/fimmu.2018.02936
  197. Alexopoulou L, Irla M. Toll-like receptors (TLRs) in the trained immunity era. Elife. 2025;14:e106443. doi: 10.7554/eLife.106443
  198. Champagne-Jorgensen K, Luong T, Darby T, Roach DR. Immunogenicity of bacteriophages. Trends Microbiol. 2023;31(10):1058-1071. doi: 10.1016/j.tim.2023.04.008
  199. Roach DR, Leung CY, Henry M, et al. Synergy between the Host Immune System and Bacteriophage Is Essential for Successful Phage Therapy against an Acute Respiratory Pathogen. Cell Host Microbe. 2017;22(1):38-47.e4. doi: 10.1016/j.chom.2017.06.018
  200. Gibb B, Hyman P, Schneider CL. The Many Applications of Engineered Bacteriophages-An Overview. Pharmaceuticals. 2021;14(7):634. doi: 10.3390/ph14070634
  201. Lu Y, Yuan H, Liang S, et al. Microbial metabolite-driven immune reprogramming in tumor immunotherapy: mechanisms and therapeutic perspectives. Front Immunol. 2025;16:1603658. doi: 10.3389/fimmu.2025.1603658
  202. Vuscan P, Kischkel B, Joosten LAB, Netea MG. Microbial-induced trained immunity for cancer immunotherapy. Pharmacol Rev. 2025;77(5):100074. doi: 10.1016/j.pharmr.2025.100074
  203. Perl M, Fante MA, Herfeld K, Scherer JN, Poeck H, Thiele Orberg E. Microbiota-derived metabolites: Key modulators of cancer immunotherapies. Med. 2025;6(8):100773. doi: 10.1016/j.medj.2025.100773
  204. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018;9:1869. doi: 10.3389/fimmu.2018.01869
  205. He B, Mai Q, Pang Y, et al. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies. Front Immunol. 2023;14:1130442. doi: 10.3389/fimmu.2023.1130442
  206. Poznanski SM, Lee AJ, Nham T, et al. Combined Stimulation with Interleukin-18 and Interleukin-12 Potently Induces Interleukin-8 Production by Natural Killer Cells. J Innate Immun. 2017;9(5):511-525. doi: 10.1159/000477172
  207. Dadas O, Ertay A, Cragg MS. Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives. Front Immunol. 2023;14:1147467. doi: 10.3389/fimmu.2023.1147467
  208. Susiriwatananont T, Eiamprapaporn P, Vazquez Roque M, Farraye FA, Perlman A, Chumsri S. The Gut Microbiome as a Biomarker and Therapeutic Target of Immune Checkpoint Inhibitors: A Review for Oncologists. Cells. 2025;14(22):1779. doi: 10.3390/cells14221779
  209. Cai Y, Wang Y, Hu S. Synthetic Gene Circuits Enable Sensing in Engineered Living Materials. Biosensors. 2025;15(9):556. doi: 10.3390/bios15090556
  210. Naydich AD, Nangle SN, Bues JJ, et al. Synthetic Gene Circuits Enable Systems-Level Biosensor Trigger Discovery at the Host-Microbe Interface. mSystems. 2019;4(4):e0012519. doi: 10.1128/mSystems.00125-19
  211. Dey S, Sankaran S. Engineered bacterial therapeutics with material solutions. Trends Biotechnol. 2024;42(12):1663- 1676. doi: 10.1016/j.tibtech.2024.06.011
  212. Khazem A, Schmachtenberg R, Weiand A, Sankaran A, Weber W. Engineered microbial living matter for diagnostics, prevention, and therapy. Curr Opin Biotechnol. 2025;92:103269. doi: 10.1016/j.copbio.2025.103269
  213. George DR, Danciu M, Davenport PW, Lain MR, Chappell J, Frow EK. A bumpy road ahead for genetic biocontainment. Nat Commun. 2024;15(1). doi: 10.1038/s41467-023-44531-1
  214. Santollani L, Maiorino L, Zhang YJ, et al. Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity. Nat Immunol. 2024;25(10):1820-1829. doi: 10.1038/s41590-024-01925-7
  215. Crow YJ, Stetson DB. The type I interferonopathies: 10 years on. Nat Rev Immunol. 2022;22(8):471-483. doi: 10.1038/s41577-021-00633-9
  216. Xia JY, Hepler C, Tran P, Waldeck NJ, Bass J, Prindle A. Engineered calprotectin-sensing probiotics for IBD surveillance in humans. Proc Natl Acad Sci USA. 2023;120(32):e2221121120. doi: 10.1073/pnas.2221121120
  217. Guo Q, Jin Y, Chen X, et al. NF-kappaB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther. 2024;9(1). doi: 10.1038/s41392-024-01757-9
  218. Neurath MF, Artis D, Becker C. The intestinal barrier: a pivotal role in health, inflammation, and cancer. Lancet Gastroenterol Hepatol. 2025;10(6):573-592. doi: 10.1016/S2468-1253(24)00390-X
  219. Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2024;19(2):275-293. doi: 10.1007/s11739-023-03374-w
  220. Woo SG, Kim SK, Lee SG, Lee DH. Engineering probiotic Escherichia coli for inflammation-responsive indoleacetic acid production using RiboJ-enhanced genetic circuits. J Biol Eng. 2025;19(1). doi: 10.1186/s13036-025-00479-y
  221. Fu L, Upadhyay R, Pokrovskii M, et al. PRDM16- dependent antigen-presenting cells induce tolerance to gut antigens. Nature. 2025;642(8068):756-765. doi: 10.1038/s41586-025-08982-4
  222. Choi Y, Lichterman JN, Coughlin LA, et al. Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity. Sci Immunol. 2023;8(81):eabo2003. doi: 10.1126/sciimmunol.abo2003
  223. Yin R, Melton S, Huseby ES, Kardar M, Chakraborty AK. How persistent infection overcomes peripheral tolerance mechanisms to cause T cell-mediated autoimmune disease. Proc Natl Acad Sci USA. 2024;121(11):e2318599121. doi: 10.1073/pnas.2318599121
  224. Li Z, Shang D. NOD1 and NOD2: Essential Monitoring Partners in the Innate Immune System. Curr Issues Mol Biol. 2024;46(9):9463-9479. doi: 10.3390/cimb46090561
  225. Movert E, Bolarin JS, Valfridsson C, et al. Interplay between human STING genotype and bacterial NADase activity regulates inter-individual disease variability. Nat Commun. 2023;14(1). doi: 10.1038/s41467-023-39771-0
  226. Clasen SJ, Bell MEW, Borbon A, et al. Silent recognition of flagellins from human gut commensal bacteria by Toll-like receptor 5. Sci Immunol. 2023;8(79):eabq7001. doi: 10.1126/sciimmunol.abq7001
  227. Chen MY, Cheng TW, Pan YC, et al. Endotoxin-Free Outer Membrane Vesicles for Safe and Modular Anticancer Immunotherapy. ACS Synth Biol. 2025;14(1):148-160. doi: 10.1021/acssynbio.4c00483
  228. Vasquez Ayala A, Hsu CY, Oles RE, et al. Commensal bacteria promote type I interferon signaling to maintain immune tolerance in mice. J Exp Med. 2024;221(1):e20230063. doi: 10.1084/jem.20230063
  229. Brockmann L, Tran A, Huang Y, et al. Intestinal microbiota-specific Th17 cells possess regulatory properties and suppress effector T cells via c-MAF and IL-10. Immunity. 2023;56(12):2719-2735.e7. doi: 10.1016/j.immuni.2023.11.003
  230. Montero-Blay A, Blanco JD, Rodriguez-Arce I, et al. Bacterial expression of a designed single-chain IL-10 prevents severe lung inflammation. Mol Syst Biol. 2024;19(1). doi: 10.15252/msb.202211037
  231. Zhernakova DV, Wang D, Liu L, et al. Host genetic regulation of human gut microbial structural variation. Nature. 2024;625(7996):813-821. doi: 10.1038/s41586-023-06893-w
  232. Moorlag S, Folkman L, Ter Horst R, et al. Multi-omics analysis of innate and adaptive responses to BCG vaccination reveals epigenetic cell states that predict trained immunity. Immunity. 2024;57(1):171-187.e14. doi: 10.1016/j.immuni.2023.12.005
  233. Berkson JD, Wate CE, Allen GB, et al. Phage-specific immunity impairs efficacy of bacteriophage targeting Vancomycin Resistant Enterococcus in a murine model. Nat Commun. 2024;15(1). doi: 10.1038/s41467-024-47192-w
  234. Tan X, Chen K, Jiang Z, et al. Evaluation of the impact of repeated intravenous phage doses on mammalian host-phage interactions. J Virol. 2024;98(1):e0135923. doi: 10.1128/jvi.01359-23
  235. Raman V, Howell LM, Bloom SMK, et al. Intracellular Salmonella delivery of an exogenous immunization antigen refocuses CD8 T cells against cancer cells, eliminates pancreatic tumors and forms antitumor immunity. Front Immunol. 2023;14:1228532. doi: 10.3389/fimmu.2023.1228532
  236. Bousbaine D, Bauman KD, Chen YE, et al. Discovery and engineering of the antibody response to a prominent skin commensal. Nature. 2025;638(8052):1054-1064. doi: 10.1038/s41586-024-08489-4
  237. Gribonika I, Band VI, Chi L, et al. Skin autonomous antibody production regulates host-microbiota interactions. Nature. 2025;638(8053):E6. doi: 10.1038/s41586-025-08776-8
  238. Viney M, Cheynel L. Gut immune responses and evolution of the gut microbiome-a hypothesis. Discov Immunol. 2023;2(1):kyad025. doi: 10.1093/discim/kyad025
  239. Mazzolini R, Rodriguez-Arce I, Fernandez-Barat L, et al. Engineered live bacteria suppress Pseudomonas aeruginosa infection in mouse lung and dissolve endotracheal-tube biofilms. Nat Biotechnol. 2023;41(8):1089-1098. doi: 10.1038/s41587-022-01584-9
  240. Fang Z, Zhong W, Xiong H, et al. Dual-Membrane- Camouflaged Engineered Bacteria for Targeted Melanoma Therapy. ACS Nano. 2025;19(51):42897-42915. doi: 10.1021/acsnano.5c16163
  241. May KL, Akiyama T, Parker BG, Kim M, Grabowicz M. LPS O-antigen polysaccharide length impacts outer membrane permeability of enteric gram-negative bacteria. mBio. 2025;16(12):e0251825. doi: 10.1128/mbio.02518-25
  242. Asada N, Ginsberg P, Paust HJ, et al. The integrated stress response pathway controls cytokine production in tissue-resident memory CD4(+) T cells. Nat Immunol. 2025;26(4):557-566. doi: 10.1038/s41590-025-02105-x
  243. Rousseau M, Lacerda Mariano L, Canton T, Ingersoll MA. Tissue-resident memory T cells mediate mucosal immunity to recurrent urinary tract infection. Sci Immunol. 2023;8(83):eabn4332. doi: 10.1126/sciimmunol.abn4332
  244. Verma S, Dufort MJ, Olsen TM, et al. Antigen-level resolution of commensal-specific B cell responses can be enabled by phage display screening coupled with B cell tetramers. Immunity. 2024;57(6):1428-1441.e8. doi: 10.1016/j.immuni.2024.04.014
  245. Rusconi B, Bard AK, McDonough R, et al. Intergenerational protective anti-gut commensal immunoglobulin G originates in early life. Proc Natl Acad Sci USA. 2024;121(13):e2309994121. doi: 10.1073/pnas.2309994121
  246. Gutzeit C, Grasset EK, Matthews DB, et al. Gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses. Sci Adv. 2025;11(7):eado9455. doi: 10.1126/sciadv.ado9455
  247. Foo GW, Uruthirapathy AS, Zhang CQ, Batko IZ, Heinrichs DE, Edgell DR. Genetic Entanglement Enables Ultrastable Biocontainment in the Mammalian Gut. ACS Synth Biol. 2025;14(9):3696-3708. doi: 10.1021/acssynbio.5c00412
  248. Heavey MK, Durmusoglu D, Crook N, Anselmo AC. Discovery and delivery strategies for engineered live biotherapeutic products. Trends Biotechnol. 2022;40(3):354- 369. doi: 10.1016/j.tibtech.2021.08.002
  249. Brittain NY, Finbloom JA. Bioinspired approaches to encapsulate and deliver bacterial live biotherapeutic products. Adv Drug Deliv Rev. 2025;225:115663. doi: 10.1016/j.addr.2025.115663
  250. Roslan MAM, Omar MN, Sharif NAM, et al. Recent advances in single-cell engineered live biotherapeutic products research for skin repair and disease treatment. NPJ Biofilms Microbiomes. 2023;9(1). doi: 10.1038/s41522-023-00463-8
  251. Buss MT, Zhu L, Kwon JH, Tabor JJ, Shapiro MG. Probiotic acoustic biosensors for noninvasive imaging of gut inflammation. Nat Commun. 2025;16(1). doi: 10.1038/s41467-025-62569-1
  252. Grome MW, Nguyen MTA, Moonan DW, et al. Engineering a genomically recoded organism with one stop codon. Nature. 2025;639(8054):512-521. doi: 10.1038/s41586-024-08501-x
  253. Gomez-Tatay L, Hernandez-Andreu JM. Xenobiology for the Biocontainment of Synthetic Organisms: Opportunities and Challenges. Life. 2024;14(8):996. doi: 10.3390/life14080996
  254. Stirling F, Naydich A, Bramante J, et al. Synthetic Cassettes for pH-Mediated Sensing, Counting, and Containment. Cell Rep. 2020;30(9):3139-3148.e4. doi: 10.1016/j.celrep.2020.02.033
  255. Liguori F, Pellicciotta N, Milanetti E, et al. Dynamic Gene Expression Mitigates Mutational Escape in Lysis-Driven Bacteria Cancer Therapy. Biodes Res. 2024;6:0049. doi: 10.34133/bdr.0049
  256. Gross JL, Basu R, Bradfield CJ, et al. Bactericidal antibiotic treatment induces damaging inflammation via TLR9 sensing of bacterial DNA. Nat Commun. 2024;15(1). doi: 10.1038/s41467-024-54497-3
  257. Yu Q, Wang L, Zhang Z, et al. Synergistic Antibacteria and Anti-Inflammation with Reversible Redox Selenium- Functionalized Polypeptides for Efficient Gram-Negative Bacterial Sepsis Treatment. Small. 2025. doi: 10.1002/smll.202509805
  258. Nyerges A, Vinke S, Flynn R, et al. A swapped genetic code prevents viral infections and gene transfer. Nature. 2023;615(7953):720-727. doi: 10.1038/s41586-023-05824-z
  259. Choi YN, Kim D, Lee S, Shin YR, Lee JW. Quadruplet codon decoding-based versatile genetic biocontainment system. Nucleic Acids Res. 2025;53(1):gkae1292. doi: 10.1093/nar/gkae1292
  260. Tran KM, Nong NT, Ren J, et al. Genetic “expiry-date” circuits control lifespan of synthetic scavenger bacteria for safe bioremediation. Nucleic Acids Res. 2025;53(14):gkaf703. doi: 10.1093/nar/gkaf703
  261. Parra ER, Zhang J, Duose DY, et al. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial. Clin Cancer Res. 2024;30(8):1655-1668. doi: 10.1158/1078-0432.CCR-23-0251
  262. Barras D, Ghisoni E, Chiffelle J, et al. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma. Sci Immunol. 2024;9(92):eadg7995. doi: 10.1126/sciimmunol.adg7995
  263. Shiao SL, Gouin KH 3rd, Ing N, et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell. 2024;42(1):70-84.e8. doi: 10.1016/j.ccell.2023.12.012
  264. Lee SY, Lee Y. Fibroblast TGF-beta signaling defines spatial tumor ecosystems linked to immune checkpoint blockade resistance. Commun Biol. 2025;8(1). doi: 10.1038/s42003-025-09087-4
  265. Synnott D, O’Reilly D, De Freitas D, Naidoo J. Cytokine release syndrome in solid tumors. Cancer. 2025;131(17):e70069. doi: 10.1002/cncr.70069
  266. Brennan AM. Development of synthetic biotics as treatment for human diseases. Synth Biol. 2022;7(1):ysac001. doi: 10.1093/synbio/ysac001
  267. Grau Bejar JF, Yaniz Galende E, Zeng Q, et al. Immune predictors of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer. J Immunother Cancer. 2024;12(7):e009143. doi: 10.1136/jitc-2024-009143
  268. Tsimberidou AM, Alayli FA, Okrah K, et al. Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. J Exp Med. 2024;221(10):e20240152. doi: 10.1084/jem.20240152
  269. Walsh MJ, Ali LR, Lenehan P, et al. Blockade of innate inflammatory cytokines TNF alpha, IL-1beta, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression. Immunother Adv. 2023;3(1):ltad019. doi: 10.1093/immadv/ltad019
  270. Soler MF, Abaurrea A, Azcoaga P, Araujo AM, Caffarel MM. New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J Immunother Cancer. 2023;11(11):e007530. doi: 10.1136/jitc-2023-007530
  271. Mennillo E, Kim YJ, Lee G, et al. Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis. Nat Commun. 2024;15(1). doi: 10.1038/s41467-024-45665-6
  272. Thomas T, Friedrich M, Rich-Griffin C, et al. A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease. Nat Immunol. 2024;25(11):2152-2165. doi: 10.1038/s41590-024-01994-8
  273. Siebert K, Faro T, Kohler N, et al. Endoscopic healing in pediatric IBD perpetuates a persistent signature defined by Th17 cells with molecular and microbial drivers of disease. Cell Rep Med. 2025;6(7):102236. doi: 10.1016/j.xcrm.2025.102236
  274. Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023;56(10):2188-2205. doi: 10.1016/j.immuni.2023.09.011
  275. Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602-609. doi: 10.1126/science.abb5920
  276. Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595-602. doi: 10.1126/science.abf3363
  277. Li D, Zhong J, Zhang Q, Zhang J. Effects of anti-inflammatory therapies on glycemic control in type 2 diabetes mellitus. Front Immunol. 2023;14:1125116. doi: 10.3389/fimmu.2023.1125116
  278. Samovski D, Smith GI, Palacios H, et al. Effect of Marked Weight Loss on Adipose Tissue Biology in People With Obesity and Type 2 Diabetes. Diabetes Care. 2025;48(8):1342- 1351. doi: 10.2337/dc24-2739
  279. Miranda AMA, McAllan L, Mazzei G, et al. Selective remodelling of the adipose niche in obesity and weight loss. Nature. 2025;644(8077):769-779. doi: 10.1038/s41586-025-09233-2
  280. Jara M, Norlin J, Kjaer MS, et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med. 2025;31(9):3128-3140. doi: 10.1038/s41591-025-03799-0
  281. Bułdak Ł, Bołdys A, Skudrzyk E, Machnik G, Okopień B. Liraglutide Therapy in Obese Patients Alters Macrophage Phenotype and Decreases Their Tumor Necrosis Factor Alpha Release and Oxidative Stress Markers-A Pilot Study. Metabolites. 2024;14(10):554. doi: 10.3390/metabo14100554
  282. Su M, Chen L, Xie L, et al. Identification of early predictive biomarkers for severe cytokine release syndrome in pediatric patients with chimeric antigen receptor T-cell therapy. Front Immunol. 2024;15:1450173. doi: 10.3389/fimmu.2024.1450173
  283. Kim GD, Shin SI, Sun P, et al. Single-cell RNA sequencing of baseline PBMCs predicts ICI efficacy and irAE severity in patients with NSCLC. J Immunother Cancer. 2025;13(1):e011636. doi: 10.1136/jitc-2025-011636
  284. Daugherty-Lopes A, Perez-Guijarro E, Gopalan V, et al. Immune and Molecular Correlates of Response to Immunotherapy Revealed by Brain-Metastatic Melanoma Models. bioRxiv. 2024. doi: 10.1101/2024.08.26.609785
  285. Chupp DP, Rivera CE, Zhou Y, et al. A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses. Nat Immunol. 2024;25(8):1489-1506. doi: 10.1038/s41590-024-01880-3
  286. Sefik E, Philbrick W, Zhang F, et al. Humanization of CD47 enables development of functional human neutrophils via postirradiation remodeling of the bone marrow. Proc Natl Acad Sci USA. 2025;122(38):e2426546122. doi: 10.1073/pnas.2426546122
  287. Knight HR, Kim M, Kannan N, et al. Bioengineering approaches to trained immunity: Physiologic targets and therapeutic strategies. Elife. 2025;14:e106339. doi: 10.7554/eLife.106339
  288. Greene C, Connolly R, Brennan D, et al. Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci. 2024;27(3):421-432. doi: 10.1038/s41593-024-01576-9
  289. Singhal T, Cicero S, Rissanen E, et al. Glial Activity Load on PET Reveals Persistent “Smoldering” Inflammation in MS Despite Disease-Modifying Treatment: 18 F-PBR06 Study. Clin Nucl Med. 2024;49(6):491-499. doi: 10.1097/RLU.0000000000005201
  290. Hirata K, Matsuoka K, Tagai K, et al. Altered Brain Energy Metabolism Related to Astrocytes in Alzheimer’s Disease. Ann Neurol. 2024;95(1):104-115. doi: 10.1002/ana.26797
  291. An M, Mehta A, Min BH, et al. Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer. Cancer Discov. 2024;14(5):766- 785. doi: 10.1158/2159-8290.CD-23-0857
  292. Chen Y, Wang D, Li Y, et al. Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer. Cancer Cell. 2024;42(7):1268-1285.e7. doi: 10.1016/j.ccell.2024.06.009
  293. Wong CK, McLean BA, Baggio LL, et al. Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation. Cell Metab. 2024;36(1):130- 143.e5. doi: 10.1016/j.cmet.2023.11.009
  294. Ramirez-Valle F, Maranville JC, Roy S, Plenge RM. Sequential immunotherapy: towards cures for autoimmunity. Nat Rev Drug Discov. 2024;23(9):501-524. doi: 10.1038/s41573-024-00959-8

295. Greco R, Alexander T, Del Papa N, et al. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. EClinicalMedicine. 2024;69:102476. doi: 10.1016/j.eclinm.2024.102476

Next article in this issue
Share
Back to top
Microbes & Immunity, Electronic ISSN: 3029-2883 Print ISSN: 3041-0886, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept